Alpine Global Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Alpine Global Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11,473	Closed	-$104K	–	210
2017 Q4	$104K	Buy	+11,473	New	+$84.4K	0.02%	153
2016 Q3	–	Sell	-20,488	Closed	-$61K	–	188
2016 Q2	$61K	Buy	+20,488	New	+$84.1K	0.03%	156

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Alpine Global Management's DRNA Position: Q1 2018 in Review

Alpine Global Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2018, closing a stake of 11,473 shares — an estimated $104K sold.

Alpine Global Management first reported a position in DRNA in Q2 2016 and held it in 2 quarters. The position peaked at $104K in Q4 2017. 72 funds tracked by Wall St. Rank hold DRNA as of Q1 2018.

Alpine Global Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Alpine Global Management sold 11,473 Dicerna Pharmaceuticals, Inc. shares in Q1 2018, an estimated $104K.
Alpine Global Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
Alpine Global Management's Dicerna Pharmaceuticals, Inc. position peaked at $104K in Q4 2017.
72 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2018.

Based on Alpine Global Management's 13F filing for Q1 2018, filed 16 May 2018.